Improved Quality of Life upon Shifting from Darbepoetin to Luspatercept in Patients with Low-Risk Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Almomen, Abdulkareem Mohammed [1 ,2 ]
Dwaima, Mohammed Eid [2 ]
Akkad, Hadeel Bashir [2 ]
Owaidah, Tarek M. [2 ]
机构：
[1] King Saud Univ, King Khalid Univ Hosp, Med, Riyadh, Saudi Arabia
[2] Natl Blood & Canc Ctr, Riyadh, Saudi Arabia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178190
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Antithymocyte globulin (ATG) plus cyclosporine (CSA) for aplastic anemia (AA) and low-risk myelodysplastic syndrome (MDS).
    Lee, Je-Hwan
    Choi, Seong-Jun
    Lee, Jung-Hee
    Seol, Miee
    Kim, Keun Hee
    Park, Jae-Hoo
    Kim, Hawk
    Joo, Young-Don
    Lee, Won-Sik
    Zang, Dae Young
    Kim, Hyo Jung
    Lee, Kyoo Hyung
    BLOOD, 2006, 108 (11) : 19B - 19B
  • [32] Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function
    Roberto Castelli
    Giorgio Lambertenghi Deliliers
    Riccardo Colombo
    Guido Moreo
    Paolo Gallipoli
    Giuseppe Pantaleo
    Annals of Hematology, 2014, 93 : 1523 - 1529
  • [33] Recombinant human erythropoietin improves quality of life and brain function in elderly patients with low-risk myelodysplastic syndromes
    Castelli, R.
    Aricci, C.
    Orofino, N.
    Moreo, G.
    Gatti, L.
    Schinco, G.
    Cugno, M.
    LEUKEMIA RESEARCH, 2013, 37 : S163 - S163
  • [34] Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function
    Castelli, Roberto
    Deliliers, Giorgio Lambertenghi
    Colombo, Riccardo
    Moreo, Guido
    Gallipoli, Paolo
    Pantaleo, Giuseppe
    ANNALS OF HEMATOLOGY, 2014, 93 (09) : 1523 - 1529
  • [35] Evaluation of Red Blood Cell Metabolism in Patients with Low-Risk Myelodysplastic Syndrome (LR-MDS): A Proof-ofConcept Study
    Fattizzo, Bruno
    Vercellati, Cristina
    Marcello, Anna
    Bortolotti, Marta
    Zaninoni, Anna
    Fermo, Elisa
    Bianchi, Paola
    Barcellini, Wilma
    BLOOD, 2022, 140 : 4016 - 4017
  • [36] Luspatercept Response in ESA-NaiVe/RS plus Patients and RS-Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)
    Platzbecker, Uwe
    Germing, Ulrich
    Gotze, Katharina
    Kiewe, Philipp
    Wolff, Thomas
    Mayer, Karin
    Chromik, Joerg
    Radsak, Markus
    Donovan, Eileen
    Wilson, Dawn M.
    Zhang, Xiaosha
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Attie, Kenneth M.
    Giagounidis, Aristoteles
    BLOOD, 2016, 128 (22)
  • [37] Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes: Exploratory analysis of baseline predictors of response.
    Gabrilove, J.
    Paquette, R.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Lam, H.
    Dreiling, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 356S - 356S
  • [38] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    BLOOD, 2017, 130
  • [39] Evidence of polyclonal hematopoiesis in a large proportion of patients with low-risk myelodysplastic syndrome.
    Malcovati, L
    Della Porta, MG
    Galli, A
    Boggi, S
    Malabarba, L
    Pietra, D
    Passamonti, F
    Bergamaschi, G
    Lazzarino, M
    Cazzola, M
    BLOOD, 2004, 104 (11) : 649A - 650A
  • [40] Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome
    Novotna, Bozena
    Bagryantseva, Yana
    Siskova, Magda
    Neuwirtova, Radana
    LEUKEMIA RESEARCH, 2009, 33 (02) : 340 - 343
12345